Harrow Inc., a prominent player in the health care sector, operates within the pharmaceuticals industry, focusing on the discovery, development, and commercialization of ophthalmic pharmaceutical products. Based in Nashville, Tennessee, the company is dedicated to providing medications for various eye conditions, including dry eye disease, glaucoma, allergies, infections, and other ophthalmic inflammatory conditions. Harrow Inc. is publicly traded on the Nasdaq stock exchange, with its shares denominated in USD.
As of January 22, 2026, Harrow Inc.’s stock closed at $44.47, reflecting a slight decrease from its latest trading day closing price of $45.32. Despite this, the stock remains below its 52-week high of $54.85, achieved on January 6, 2026. Over the past year, Harrow’s share price has experienced significant fluctuations, ranging from a low of $20.85 on April 8, 2025, to the aforementioned high. This volatility is indicative of the broader trends and uncertainties within the pharmaceutical sector.
The company’s market capitalization stands at approximately $1.68 billion USD, underscoring its substantial presence in the industry. However, Harrow Inc. faces challenges in terms of profitability, as evidenced by its price-to-earnings ratio of -336.47. This negative ratio highlights the company’s current lack of earnings, which may be attributed to ongoing investments in research and development or other operational factors.
Valuation metrics further reveal a price-to-earnings ratio of 2,491.81 and a price-to-book ratio of 35.69. These figures suggest that the market is pricing Harrow’s future earnings potential and equity base at a premium, despite the absence of current earnings. Such high multiples may reflect investor confidence in the company’s long-term growth prospects and its strategic focus on innovative ophthalmic solutions.
In terms of recent news, Harrow Inc. has maintained a low profile, with no significant announcements beyond an analysis piece published on January 4, 2026. The article, titled “Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and Pharvaris (PHVS),” provided an overview of the company’s position within the healthcare landscape. This lack of recent news may contribute to the stock’s volatility, as investors navigate the uncertainties surrounding the company’s future performance.
Overall, Harrow Inc. remains a key player in the pharmaceuticals sector, with a strong focus on ophthalmic products. While the company faces challenges related to profitability and market volatility, its strategic initiatives and market valuation suggest a positive outlook for future growth. For more detailed information on Harrow Inc.’s activities and developments, stakeholders are encouraged to visit the company’s website at www.harrow.com .
